Recruiting studies: Stage Iii Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carbo
Phase 2 · 34 location(s) · National Cancer Institute (NCI) · NCT05198830 Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3 · 1 location(s) · Tata Memorial Hospital · NCT05236946 Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924 Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127 A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179 Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT04631770 Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherap
NA · 3 location(s) · City of Hope Medical Center · NCT06139627 IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635 A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751 Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC
NA · 2 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07003490 A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable
Phase 3 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT04951635 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060 Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
Phase 3 · 6 location(s) · Vastra Gotaland Region · NCT06141070 First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Ca
Phase 3 · 3 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06840782 A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07362459 A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Phase N/A · 1 location(s) · AstraZeneca · NCT07316062 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit
Phase 3 · 37 location(s) · Allist Pharmaceuticals, Inc. · NCT06416410 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-L
Phase 3 · 403 location(s) · Amgen · NCT05920356 Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07609121 Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 345 location(s) · National Cancer Institute (NCI) · NCT03191149 Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2/Phase 3 · 11 location(s) · Swiss Cancer Institute · NCT07149649 The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment
Phase 2 · 1 location(s) · The Third Xiangya Hospital of Central South University · NCT07138755 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · 260 location(s) · Hoffmann-La Roche · NCT06793215 Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Phase N/A · 22 location(s) · Fundación GECP · NCT06634199 A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Phase 3 · 7 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT04316364 Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Phase 2 · 5 location(s) · University Hospital, Bonn · NCT06810609 Pathological Response After Neoadjuvant Treatment on NSCLC
Phase N/A · 17 location(s) · Fundación GECP · NCT05167487 The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06623487 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC H
Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT07336732 Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Phase N/A · 6 location(s) · University Medical Center Groningen · NCT06111807

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.